Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer: biomarker evaluation of the IMpassion130 study
Understanding the impact of the tumor immune microenvironment and BRCA1/2-related DNA repair deficiencies on the clinical activity of immune checkpoint inhibitors may help optimize both patient and treatment selection in metastatic triple-negative breast cancer. In this substudy from the phase 3 IMp...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
01 February 2021
|
| In: |
Journal of the National Cancer Institute
Year: 2021, Volume: 113, Issue: 8, Pages: 1005-1016 |
| ISSN: | 1460-2105 |
| DOI: | 10.1093/jnci/djab004 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1093/jnci/djab004
|
| Author Notes: | Leisha A. Emens, MD, PhD, Luciana Molinero, PhD, Sherene Loi, MD, PhD, Hope S. Rugo, MD, Andreas Schneeweiss, MD, Véronique Diéras, MD, Hiroji Iwata, MD, PhD, Carlos H. Barrios, MD, Marina Nechaeva, MD, Anh Nguyen-Duc, PhD, Stephen Y. Chui, MD, Amreen Husain, MD, Eric P. Winer, MD, Sylvia Adams, MD, Peter Schmid, MD, PhD |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1780841094 | ||
| 003 | DE-627 | ||
| 005 | 20220820091734.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 211209s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/jnci/djab004 |2 doi | |
| 035 | |a (DE-627)1780841094 | ||
| 035 | |a (DE-599)KXP1780841094 | ||
| 035 | |a (OCoLC)1341434661 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Emens, Leisha Ann |e VerfasserIn |0 (DE-588)1139674196 |0 (DE-627)897410122 |0 (DE-576)493389598 |4 aut | |
| 245 | 1 | 0 | |a Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer |b biomarker evaluation of the IMpassion130 study |c Leisha A. Emens, MD, PhD, Luciana Molinero, PhD, Sherene Loi, MD, PhD, Hope S. Rugo, MD, Andreas Schneeweiss, MD, Véronique Diéras, MD, Hiroji Iwata, MD, PhD, Carlos H. Barrios, MD, Marina Nechaeva, MD, Anh Nguyen-Duc, PhD, Stephen Y. Chui, MD, Amreen Husain, MD, Eric P. Winer, MD, Sylvia Adams, MD, Peter Schmid, MD, PhD |
| 264 | 1 | |c 01 February 2021 | |
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 09.12.2021 | ||
| 520 | |a Understanding the impact of the tumor immune microenvironment and BRCA1/2-related DNA repair deficiencies on the clinical activity of immune checkpoint inhibitors may help optimize both patient and treatment selection in metastatic triple-negative breast cancer. In this substudy from the phase 3 IMpassion130 trial, immune biomarkers and BRCA1/2 alterations were evaluated for association with clinical benefit with atezolizumab and nab-paclitaxel (A+nP) vs placebo and nP in unresectable (P+nP) locally advanced or metastatic triple-negative breast cancer.Patients were randomly assigned 1:1 to nab-paclitaxel 100 mg/m2 (days 1, 8, and 15 of a 28-day cycle) and atezolizumab 840 mg every 2 weeks or placebo until progression or toxicity. Progression-free survival and overall survival were evaluated based on programmed death-ligand 1 (PD-L1) expression on immune cells (IC) and tumor cells, intratumoral CD8, stromal tumor-infiltrating lymphocytes, and BRCA1/2 mutations.PD-L1 IC+ in either primary or metastatic tumor tissue was linked to progression-free survival and overall survival benefit with A+nP. PD-L1 IC+ low (26.9%; 243 of 902 patients) and high (13.9%; 125 of 902 patients) populations had improved outcomes that were comparable. Intratumoral CD8 and stromal tumor-infiltrating lymphocytes positivity (sTIL+) were associated with PD-L1 IC+ status; improved outcomes were observed with A+nP vs P+nP only in CD8+ and sTIL+ patients who were also PD-L1 IC+. BRCA1/2 mutations (occurring in 14.5% [89 of 612 patients]) were not associated with PD-L1 IC status, and PD-L1 IC+ patients benefited from A+nP regardless of BRCA1/2 mutation status.Although A+nP was more efficacious in patients with richer tumor immune microenvironment, clinical benefit was only observed in patients whose tumors were PD-L1 IC+. | ||
| 700 | 1 | |a Molinero, Luciana |e VerfasserIn |4 aut | |
| 700 | 1 | |a Loi, Sherene |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rugo, Hope S |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schneeweiss, Andreas |d 1961- |e VerfasserIn |0 (DE-588)109972554 |0 (DE-627)632849630 |0 (DE-576)327251859 |4 aut | |
| 700 | 1 | |a Diéras, Véronique |e VerfasserIn |4 aut | |
| 700 | 1 | |a Iwata, Hiroji |e VerfasserIn |4 aut | |
| 700 | 1 | |a Barrios, Carlos H |e VerfasserIn |4 aut | |
| 700 | 1 | |a Nechaeva, Marina |e VerfasserIn |4 aut | |
| 700 | 1 | |a Nguyen-Duc, Anh |e VerfasserIn |4 aut | |
| 700 | 1 | |a Chui, Stephen Y |e VerfasserIn |4 aut | |
| 700 | 1 | |a Husain, Amreen |e VerfasserIn |4 aut | |
| 700 | 1 | |a Winer, Eric P |e VerfasserIn |4 aut | |
| 700 | 1 | |a Adams, Sylvia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schmid, Peter |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |a National Cancer Institute |t Journal of the National Cancer Institute |d Oxford : Oxford Univ. Press, 1941 |g 113(2021), 8 vom: Aug., Seite 1005-1016 |w (DE-627)265780713 |w (DE-600)1465951-7 |w (DE-576)074959581 |x 1460-2105 |7 nnas |
| 773 | 1 | 8 | |g volume:113 |g year:2021 |g number:8 |g month:08 |g pages:1005-1016 |g extent:12 |a Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer biomarker evaluation of the IMpassion130 study |
| 856 | 4 | 0 | |u https://doi.org/10.1093/jnci/djab004 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20211209 | ||
| 993 | |a Article | ||
| 994 | |a 2021 | ||
| 998 | |g 109972554 |a Schneeweiss, Andreas |m 109972554:Schneeweiss, Andreas |d 910000 |d 910400 |d 50000 |e 910000PS109972554 |e 910400PS109972554 |e 50000PS109972554 |k 0/910000/ |k 1/910000/910400/ |k 0/50000/ |p 5 | ||
| 999 | |a KXP-PPN1780841094 |e 4017862462 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"id":{"doi":["10.1093/jnci/djab004"],"eki":["1780841094"]},"physDesc":[{"extent":"12 S."}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"title":[{"subtitle":"biomarker evaluation of the IMpassion130 study","title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","title_sort":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer"}],"origin":[{"dateIssuedDisp":"01 February 2021","dateIssuedKey":"2021"}],"relHost":[{"recId":"265780713","origin":[{"publisher":"Oxford Univ. Press","dateIssuedDisp":"1941-","dateIssuedKey":"1941","publisherPlace":"Oxford"}],"title":[{"title_sort":"Journal of the National Cancer Institute","title":"Journal of the National Cancer Institute","subtitle":"JNCI"}],"id":{"zdb":["1465951-7"],"issn":["1460-2105"],"eki":["265780713"]},"note":["Gesehen am 18.02.14"],"pubHistory":["1.1940/41(1941) -"],"language":["eng"],"part":{"year":"2021","volume":"113","extent":"12","pages":"1005-1016","issue":"8","text":"113(2021), 8 vom: Aug., Seite 1005-1016"},"titleAlt":[{"title":"Journal of the National Cancer Institute online"},{"title":"JNCI"}],"corporate":[{"role":"aut","display":"National Cancer Institute"}],"disp":"National Cancer InstituteJournal of the National Cancer Institute","type":{"media":"Online-Ressource","bibl":"periodical"}}],"name":{"displayForm":["Leisha A. Emens, MD, PhD, Luciana Molinero, PhD, Sherene Loi, MD, PhD, Hope S. Rugo, MD, Andreas Schneeweiss, MD, Véronique Diéras, MD, Hiroji Iwata, MD, PhD, Carlos H. Barrios, MD, Marina Nechaeva, MD, Anh Nguyen-Duc, PhD, Stephen Y. Chui, MD, Amreen Husain, MD, Eric P. Winer, MD, Sylvia Adams, MD, Peter Schmid, MD, PhD"]},"language":["eng"],"note":["Gesehen am 09.12.2021"],"person":[{"role":"aut","family":"Emens","display":"Emens, Leisha Ann","given":"Leisha Ann"},{"role":"aut","family":"Molinero","display":"Molinero, Luciana","given":"Luciana"},{"family":"Loi","role":"aut","display":"Loi, Sherene","given":"Sherene"},{"family":"Rugo","role":"aut","given":"Hope S","display":"Rugo, Hope S"},{"family":"Schneeweiss","role":"aut","display":"Schneeweiss, Andreas","given":"Andreas"},{"family":"Diéras","role":"aut","display":"Diéras, Véronique","given":"Véronique"},{"role":"aut","family":"Iwata","display":"Iwata, Hiroji","given":"Hiroji"},{"display":"Barrios, Carlos H","given":"Carlos H","family":"Barrios","role":"aut"},{"display":"Nechaeva, Marina","given":"Marina","role":"aut","family":"Nechaeva"},{"display":"Nguyen-Duc, Anh","given":"Anh","family":"Nguyen-Duc","role":"aut"},{"display":"Chui, Stephen Y","given":"Stephen Y","family":"Chui","role":"aut"},{"display":"Husain, Amreen","given":"Amreen","family":"Husain","role":"aut"},{"role":"aut","family":"Winer","given":"Eric P","display":"Winer, Eric P"},{"family":"Adams","role":"aut","given":"Sylvia","display":"Adams, Sylvia"},{"display":"Schmid, Peter","given":"Peter","family":"Schmid","role":"aut"}],"recId":"1780841094"} | ||
| SRT | |a EMENSLEISHATEZOLIZUM0120 | ||